US set to pay nearly $2B for Pfizer's Covid-19 treatment Paxlovid in 2023
The US government is teeing up more Pfizer Covid-19 antiviral purchases for next year – to the tune of $2 billion.
Pfizer’s new agreement with the feds adds 3.7 million treatment courses of Paxlovid to the government’s tally. To date, 20 million courses of treatment have already been contracted and delivered, with the newest batch set for delivery early next year.
The Department of Defense contract lands just under $2 billion for the 3.7 million courses. That’s in line with Pfizer’s original deal with the US government for around $10.6 billion for the first 20 million, which netted out to about $530 per treatment course.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
